Table 4.
Long-term cost-effectiveness outcomes in the base case analysis
| Health outcomes | Once-weekly semaglutide 0.5 mg | Dulaglutide 1.5 mg | Difference |
|---|---|---|---|
| Discounted life expectancy (years) | 11.61 (0.15) | 11.57 (0.15) | + 0.04 |
| Discounted quality-adjusted life expectancy (QALYs) | 7.19 (0.09) | 7.16 (0.10) | + 0.04 |
| Discounted direct costs (EUR) | 18,686 (399) | 18,706 (404) | − 20 |
| ICER based on life expectancy and direct costs | Once-weekly semaglutide 0.5 mg dominant | ||
| ICER based on quality-adjusted life expectancy and direct costs | Once-weekly semaglutide 0.5 mg dominant | ||
| Health outcomes | Once-weekly semaglutide 1 mg | Dulaglutide 1.5 mg | Difference |
|---|---|---|---|
| Discounted life expectancy (years) | 11.63 (0.15) | 11.57 (0.15) | + 0.06 |
| Discounted quality-adjusted life expectancy (QALYs) | 7.23 (0.10) | 7.16 (0.10) | + 0.07 |
| Discounted direct costs (EUR) | 18,566 (402) | 18,706 (404) | − 140 |
| ICER based on life expectancy and direct costs | Once-weekly semaglutide 1 mg dominant | ||
| ICER based on quality-adjusted life expectancy and direct costs | Once-weekly semaglutide 1 mg dominant | ||
Values are means (standard deviations)
EUR euros, ICER incremental cost-effectiveness ratio, QALYs quality-adjusted life years